<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK442323" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK442323/" /><meta name="ncbi_pagename" content="SLC6A3-Related Dopamine Transporter Deficiency Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>SLC6A3-Related Dopamine Transporter Deficiency Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="SLC6A3-Related Dopamine Transporter Deficiency Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/07/27" /><meta name="citation_author" content="Manju A Kurian" /><meta name="citation_pmid" content="28749637" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK442323/" /><meta name="citation_keywords" content="DAT Deficiency" /><meta name="citation_keywords" content="DAT Deficiency" /><meta name="citation_keywords" content="Classic Early-Onset Dopamine Transporter Deficiency Syndrome (DTDS)" /><meta name="citation_keywords" content="Atypical Later-Onset Dopamine Transporter Deficiency Syndrome (DTDS)" /><meta name="citation_keywords" content="Sodium-dependent dopamine transporter" /><meta name="citation_keywords" content="SLC6A3" /><meta name="citation_keywords" content="SLC6A3-Related Dopamine Transporter Deficiency Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="SLC6A3-Related Dopamine Transporter Deficiency Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Manju A Kurian" /><meta name="DC.Date" content="2017/07/27" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK442323/" /><meta name="description" content="SLC6A3-related dopamine transporter deficiency syndrome (DTDS) is a complex movement disorder with a continuum that ranges from classic early-onset DTDS (in the first 6 months) to atypical later-onset DTDS (in childhood, adolescence, or adulthood)." /><meta name="og:title" content="SLC6A3-Related Dopamine Transporter Deficiency Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="SLC6A3-related dopamine transporter deficiency syndrome (DTDS) is a complex movement disorder with a continuum that ranges from classic early-onset DTDS (in the first 6 months) to atypical later-onset DTDS (in childhood, adolescence, or adulthood)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK442323/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/slc6a3-dtds/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK442323/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DA0C1E0405F010000000006070241.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK442323_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK442323_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/slc39a14-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sost/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK442323_"><span class="title" itemprop="name"><i>SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: DAT Deficiency</div><p class="contrib-group"><span itemprop="author">Manju A Kurian</span>, MA, MBBChir, PhD.</p><a data-jig="ncbitoggler" href="#__NBK442323_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK442323_ai__"><div class="contrib half_rhythm"><span itemprop="author">Manju A Kurian</span>, MA, MBBChir, PhD<div class="affiliation small">Developmental Neurosciences Programme<br />UCL Institute of Child Health<br />London, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.ca.lcu@nairuk.ujnam" class="oemail">ku.ca.lcu@nairuk.ujnam</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 27, 2017</span>.</p><p><em>Estimated reading time: 17 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="slc6a3-dtds.Summary" itemprop="description"><h2 id="_slc6a3-dtds_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>SLC6A3-</i>related dopamine transporter deficiency syndrome (DTDS) is a complex movement disorder with a continuum that ranges from classic early-onset DTDS (in the first 6 months) to atypical later-onset DTDS (in childhood, adolescence, or adulthood).</p><ul><li class="half_rhythm"><div><i>Classic DTDS</i>. Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development) followed by a hyperkinetic movement disorder (with features of chorea, dystonia, ballismus, orolingual dyskinesia). Over time, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop parkinsonism-dystonia characterized by bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression. Limitation of voluntary movements leads to severe motor delay. Episodic status dystonicus, exacerbations of dystonia, and secondary orthopedic, gastrointestinal, and respiratory complications are common. Many affected individuals appear to show relative preservation of intellect with good cognitive development.</div></li><li class="half_rhythm"><div><i>Atypical DTDS</i>. Normal psychomotor development in infancy and early childhood is followed by later-onset manifestations of parkinsonism-dystonia with tremor, progressive bradykinesia, variable tone, and dystonic posturing. The long-term outcome of this form is currently unknown.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>SLC6A3-</i>related DTDS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical, laboratory, and imaging findings and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC6A3</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment to control chorea and dyskinesia in early stages of the disease includes tetrabenazine and benzodiazepines. Dystonia is more difficult to control and treatment often includes pramipexole and ropinirole as first-line agents; adjuncts such as trihexyphenidyl, baclofen, gabapentin, and clonidine for severe dystonia; and chloral hydrate and benzodiazepines for exacerbations of dystonia or status dystonicus.</p><p><i>Prevention of secondary complications:</i> Regular physiotherapy to reduce the risk of contractures; early referral for management of feeding difficulties; use of influenza vaccine, prophylactic antibiotics, and chest physiotherapy for patients prone to chest infections, especially in the winter months.</p><p><i>Surveillance:</i> Evaluation every six to 12 months for early evidence of hip dislocation and/or spinal deformity; regular assessment of swallowing to evaluate risk for aspiration; regular nutrition assessment to ensure adequate caloric intake.</p><p><i>Agents/circumstances to avoid:</i> Although the dopamine agonists bromocriptine and pergolide could be considered, the associated increased risk of pulmonary, retroperitoneal, and pericardial fibrosis makes them less desirable than the newer dopamine agonists. Drugs with anti-dopaminergic side effects (e.g., some antihistamines, sedatives, and dimenhydrinate) may exacerbate the movement disorder. For the treatment of vomiting, anti-emetics such as the anti-serotoninergic agents (e.g., ondansetron) potentially have fewer side effects than other agents.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>SLC6A3-</i>related DTDS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>SLC6A3</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives and prenatal testing or <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for pregnancies at increased risk are options that can be considered.</p></div></div><div id="slc6a3-dtds.GeneReview_Scope"><h2 id="_slc6a3-dtds_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="slc6a3-dtds.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK442323/table/slc6a3-dtds.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__slc6a3-dtds.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_slc6a3-dtds.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome: Included Phenotypes</th></tr></thead><tbody><tr><td headers="hd_h_slc6a3-dtds.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Classic early-onset dopamine transporter deficiency syndrome (DTDS)</div></li><li class="half_rhythm"><div>Atypical later-onset DTDS</div></li></ul>
</td></tr></tbody></table></div></div></div><div id="slc6a3-dtds.Diagnosis"><h2 id="_slc6a3-dtds_Diagnosis_">Diagnosis</h2><p><i>SLC6A3-</i>related dopamine transporter deficiency syndrome (DTDS) is a complex movement disorder in which the disease continuum comprises two phenotypes with overlapping clinical features:</p><ul><li class="half_rhythm"><div>Classic early-onset DTDS</div></li><li class="half_rhythm"><div>Atypical later-onset DTDS</div></li></ul><div id="slc6a3-dtds.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Classic early-onset and atypical later-onset <i>SLC6A3</i>-related dopamine transporter deficiency (DTDS) syndrome <b>should be suspected</b> in individuals with the following <a href="#slc6a3-dtds.Clinical_Findings">clinical</a> and <a href="#slc6a3-dtds.Laboratory_Findings">laboratory</a> findings.</p><div id="slc6a3-dtds.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Classic</b>
<b>early-onset DTDS</b></p><ul><li class="half_rhythm"><div><b>Predominant features in infancy</b></div><ul><li class="half_rhythm"><div>Onset usually within the first six months of life</div></li><li class="half_rhythm"><div>Early nonspecific clinical findings of irritability and difficulty feeding</div></li><li class="half_rhythm"><div>Axial hypotonia</div></li><li class="half_rhythm"><div>Delay in motor milestones</div></li><li class="half_rhythm"><div>Hyperkinetic movement disorder (chorea, ballismus, dystonia, orolingual dyskinesia) typically evident in infancy and early childhood; may persist into late childhood and adolescence</div></li><li class="half_rhythm"><div>Eye movement disorders including recurrent oculogyric crisis, saccade initiation failure, ocular flutter, and eyelid myoclonus (which is thought to be nonepileptic)</div></li></ul></li><li class="half_rhythm"><div><b>Predominant features in childhood/adolescence</b></div><ul><li class="half_rhythm"><div>Parkinsonism-dystonia including dystonic postures, resting and action tremor, difficulty initiating movements, bradykinesia, paucity of facial expression, and rigidity</div></li><li class="half_rhythm"><div>Severe delay in motor milestones</div></li><li class="half_rhythm"><div>Eye movement disorder (see classic early-onset DTDS)</div></li></ul></li></ul><p><b>Atypical later-onset DTDS: Predominant features</b></p><ul><li class="half_rhythm"><div>Onset from childhood to adulthood (4th decade)</div></li><li class="half_rhythm"><div>Attention-deficit/hyperactivity disorder (ADHD)</div></li><li class="half_rhythm"><div>Resting and action tremor</div></li><li class="half_rhythm"><div>Dysarthria</div></li><li class="half_rhythm"><div>Parkinsonism-dystonia</div></li></ul></div><div id="slc6a3-dtds.Laboratory_Findings"><h4>Laboratory Findings</h4><p><b>CSF neurotransmitter analysis.</b> To date, all individuals with classic early-onset <i>SLC6A3-</i>related DTDS have a distinct pattern:</p><ul><li class="half_rhythm"><div>Raised homovanillic acid level (HVA, metabolite derived from dopamine) with normal 5-hydroxyindoleacetic acid level (5-HIAA, metabolite derived from serotonin). The HVA:5-HIAA ratio in <i>SLC6A3-</i>related DTDS is &#x0003e;4.0 (range 5.0-13.0) (normal range 1.0-4.0)</div></li><li class="half_rhythm"><div>Normal pterin profile</div></li></ul><p><b>SPECT imaging using the ligand ioflupane (DaTScan).</b> To date, all individuals with <i>SLC6A3-</i>related DTDS who were evaluated had very abnormal results with absent/reduced tracer uptake in the basal nuclei.</p></div></div><div id="slc6a3-dtds.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>SLC6A3-</i>related DTDS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with characteristic clinical findings (especially parkinsonism-dystonia), CSF HVA:5-HIAA ratio &#x0003e;4.0, DaTScan showing reduced tracer uptake [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>], and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SLC6A3</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK442323/table/slc6a3-dtds.T.molecular_genetic_testing/?report=objectonly" target="object" rid-figpopup="figslc6a3dtdsTmoleculargenetictesting" rid-ob="figobslc6a3dtdsTmoleculargenetictesting">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> or single-gene testing) and <b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (comprehensive genomic sequencing) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires the clinician to broadly determine clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) likely to be involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Children with the distinctive early-onset findings described in <a href="#slc6a3-dtds.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#slc6a3-dtds.Option_1">Option 1</a>) but may also be identified by genomic testing. Individuals with later-onset disease in which the phenotype may show overlap with other inherited neurologic disorders (ADHD, tremor, dysarthria, and/or parkinsonism-dystonia) may be identified through gene-targeted panels but may also be diagnosed using genomic testing (see <a href="#slc6a3-dtds.Option_2">Option 2</a>).</p><div id="slc6a3-dtds.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of <i>SLC6A3-</i>related DTDS, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>SLC6A3</i> is performed first. Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> should be considered if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found. To date, the majority of variants are intragenic single-nucleotide variants, insertions, or deletions detectable by <a class="def" href="/books/n/gene/glossary/def-item/sanger-sequencing/">Sanger sequencing</a>. Two larger deletions that were detectable by deletion/duplication analysis have been identified [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>; Kurian, personal communication 2016].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SLC6A3</i> and other genes of interest (see <a href="#slc6a3-dtds.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="slc6a3-dtds.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by ADHD, tremor, dysarthria, and/or parkinsonism-dystonia, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include (when clinically available) <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>, which includes <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="slc6a3-dtds.T.molecular_genetic_testing" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK442323/table/slc6a3-dtds.T.molecular_genetic_testing/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__slc6a3-dtds.T.molecular_genetic_testing_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC6A3</i></td><td headers="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most <i>SLC6A3</i> pathogenic variants reported to date</td></tr><tr><td headers="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_slc6a3-dtds.T.molecular_genetic_testing_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="slc6a3-dtds.TF.1.1"><p class="no_margin">See <a href="/books/NBK442323/#slc6a3-dtds.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="slc6a3-dtds.TF.1.2"><p class="no_margin">See <a href="#slc6a3-dtds.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="slc6a3-dtds.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="slc6a3-dtds.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="slc6a3-dtds.TF.1.5"><p class="no_margin">Two individuals with deletions detectable by <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> have been reported (see <a href="#slc6a3-dtds.Molecular_Pathogenesis">Molecular Pathogenesis</a>, <b>Pathogenic variants</b>).</p></div></dd></dl></div></div></div></div></div></div><div id="slc6a3-dtds.Clinical_Characteristics"><h2 id="_slc6a3-dtds_Clinical_Characteristics_">Clinical Characteristics</h2><div id="slc6a3-dtds.Clinical_Description"><h3>Clinical Description</h3><p><i>SLC6A3-</i>related dopamine transporter deficiency syndrome (DTDS) typically presents in infancy and atypically later in childhood, adolescence, or adulthood [<a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2015">Kurian &#x00026; Assmann 2015</a>]. <i>SLC6A3-</i>related DTDS is rare, with fewer than 30 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (from ~21 families) identified to date [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.yildiz.2017.49">Yildiz et al 2017</a>].</p><div id="slc6a3-dtds.Classic_EarlyOnset_DTDS"><h4>Classic Early-Onset DTDS</h4><p>Typically, infants present between birth and age six months [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>]. In the early stages, children manifest the nonspecific findings of irritability, feeding difficulties, axial hypotonia, and delayed motor development. In infancy a heterogeneous movement disorder is prominent, with features of chorea, dystonia, dystonia-parkinsonism, ballismus, and orolingual dyskinesia. Many infants also develop an eye movement disorder, which may manifest as recurrent oculogyric crises, saccade initiation failure, ocular flutter, or eyelid myoclonus. At this early age hyperkinetic features predominate.</p><p>The early hyperkinesia often becomes less prominent over time, with subsequent development of parkinsonism-dystonia. Bradykinesia progressing to akinesia is common, as well as dystonic posturing, distal tremor, rigidity, and hypomimia (reduced facial expression). Voluntary movements become limited, leading to severe motor delay.</p><p>During the first years of life some children have episodic status dystonicus. Prolonged periods of crying and irritability &#x02013; without discernable triggers &#x02013; are also described. Disrupted sleep patterns are common. Exacerbations of dystonia are also common, often related to intercurrent illness, infection, and/or dehydration.</p><p>Although more data are needed, it appears that many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals show relative preservation of intellect with good cognitive development.</p><p>Secondary orthopedic, gastrointestinal, and respiratory complications are common [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2015">Kurian &#x00026; Assmann 2015</a>].</p><ul><li class="half_rhythm"><div>Many develop spinal deformities, often necessitating surgery. Fixed limb contractures, osteoporotic bone fractures, and hip dislocation are also described.</div></li><li class="half_rhythm"><div>Alternative feeding strategies using nasogastric tubes or percutaneous endoscopic gastrostomy become necessary due to progressive bulbar dysfunction.</div></li><li class="half_rhythm"><div>Reduced axial tone, spinal abnormalities, and bulbar dysfunction compromise respiratory function, leading to an increased risk for recurrent chest infections and aspiration pneumonia.</div></li><li class="half_rhythm"><div>The majority develop anarthria, and need alternative and augmentative communication devices for effective communication.</div></li></ul><p>A number of children with infantile-onset <i>SLC6A3-</i>related DTDS die in late childhood / early adolescence from unexplained sudden death in sleep or respiratory complications.</p></div><div id="slc6a3-dtds.Atypical_LaterOnset_DTDS"><h4>Atypical Later-Onset DTDS</h4><p>To date, four individuals with atypical later-onset DTDS have been described. They had normal psychomotor development in infancy and early childhood, attaining independent ambulation and spoken language [<a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>]. Later in childhood, adolescence, or adulthood, they developed manifestations of parkinsonism-dystonia with tremor, progressive bradykinesia, variable tone, and dystonic posturing.</p><p>Manifestations of ADHD in childhood have been reported.</p><p>Identification of additional individuals with later-onset DTDS will aid understanding of this atypical presentation.</p></div></div><div id="slc6a3-dtds.GenotypePhenotype_Correlatio"><h3>Genotype-Phenotype Correlations</h3><p>It is not yet clear whether <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> exist for <i>SLC6A3-</i>related DTDS.</p><p>From published functional data on pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, children with classic, severe early-onset disease have lower levels of residual transporter activity than those with the later-onset atypical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>].</p></div><div id="slc6a3-dtds.Penetrance"><h3>Penetrance</h3><p><i>SLC6A3-</i>related DTDS shows complete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> with no discernible gender differences.</p></div><div id="slc6a3-dtds.Prevalence"><h3>Prevalence</h3><p><i>SLC6A3-</i>related DTDS is rare, with fewer than 30 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals (from ~21 families) currently identified [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.yildiz.2017.49">Yildiz et al 2017</a>].</p><p>Affected individuals have been reported from a wide variety of ethnic backgrounds.</p></div></div><div id="slc6a3-dtds.Genetically_Related_Allelic"><h2 id="_slc6a3-dtds_Genetically_Related_Allelic_">Genetically Related (Allelic) Disorders</h2><p>Rare <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>SLC6A3</i> have been reported in individuals with bipolar disorder, attention-deficit/hyperactivity disorder, and autism spectrum disorder [<a class="bk_pop" href="#slc6a3-dtds.REF.hayden.2006.85">Hayden &#x00026; Nurnberger 2006</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hamilton.2013.1315">Hamilton et al 2013</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.bowton.2014.e464">Bowton et al 2014</a>] (see <a href="#slc6a3-dtds.Molecular_Genetics">Molecular Genetics</a>, <b>Pathogenic variants</b>).</p></div><div id="slc6a3-dtds.Differential_Diagnosis"><h2 id="_slc6a3-dtds_Differential_Diagnosis_">Differential Diagnosis</h2><p>The following groups of disorders can present clinically with the manifestations of classic early-onset and atypical later-onset <i>SLC6A3-</i>related DTDS.</p><p><b>Cerebral palsy.</b> The early hyperkinetic features of classic early-onset <i>SLC6A3-</i>related DTDS can mimic dyskinetic cerebral palsy and later features may be reminiscent of spastic/dystonic cerebral palsy. Details of the pre- and perinatal history and MRI, as well as the diagnostic testing specific for <i>SLC6A3-</i>related DTDS, may be helpful in differentiating these conditions.</p><p><b>Neurotransmitter disorders.</b> The clinical features of progressive parkinsonism-dystonia, eye movement disorder, axial hypotonia, and delayed motor development may be similar to those seen in other neurotransmitter disorders [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011a.721">Kurian et al 2011a</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2015.567">Ng et al 2015</a>], including <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> pterin defects (e.g., <a href="/books/n/gene/spr-def/">sepiapterin reductase deficiency</a> and autosomal recessive GTP cyclohydrolase deficiency [OMIM <a href="https://omim.org/entry/233910" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">233910</a>]), <a href="/books/n/gene/thdrd/">tyrosine hydroxylase deficiency</a>, aromatic L-amino acid decarboxylase deficiency (OMIM <a href="https://omim.org/entry/107930" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">107930</a>), and brain serotonin-dopamine deficiency caused by mutation of <i>SLC18A2</i>.</p><p><b>Mitochondrial diseases.</b> The phenotypic features of the mitochondriocytopathies (including those caused by pathogenic variants in <a href="/books/n/gene/alpers/"><i>POLG</i></a><i>,</i> pyruvate dehydrogenase deficiency (OMIM <a href="https://omim.org/entry/312170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">312170</a>), and <a href="/books/n/gene/pdc/">pyruvate carboxylase deficiency</a>) overlap with <i>SLC6A3-</i>related DTDS [<a class="bk_pop" href="#slc6a3-dtds.REF.garciacazorla.2008.273">Garcia-Cazorla et al 2008</a>]. In some mitochondrial disorders increased HVA levels are also observed [<a class="bk_pop" href="#slc6a3-dtds.REF.pineda.2006.394">Pineda et al 2006</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hasselmann.2010.58">Hasselmann et al 2010</a>].</p><p><b>Metabolic syndromes</b> including lysosomal storage diseases, <a href="/books/n/gene/npc/">Niemann-Pick disease type C</a>, <a href="/books/n/gene/gm1-ganglio/">GM1 gangliosidosis</a>, <a href="/books/n/gene/lns/">Lesch-Nyhan syndrome</a>, <a href="/books/n/gene/homocystinuria/">homocystinuria</a>, and untreated <a href="/books/n/gene/pku/">phenylketonuria</a> can mimic <i>SLC6A3-</i>related DTDS [<a class="bk_pop" href="#slc6a3-dtds.REF.garciacazorla.2014.627">Garcia-Cazorla &#x00026; Duarte 2014</a>].</p><p><b>Monogenic movement disorders associated with infantile-onset dyskinesia/hyperkinesia.</b> Early disease manifestations of classic early-onset DTDS may be reminiscent of <a href="/books/n/gene/adcy5-dysk/"><i>ADCY5</i>-related dyskinesia</a>, <a href="/books/n/gene/glut1/">glucose transporter type 1 deficiency syndrome</a>, <i>PRRT2</i>-related paroxysmal kinesigenic dyskinesia with infantile convulsions (see <a href="/books/n/gene/prrt2-parox/"><i>PRRT2</i>-Associated Paroxysmal Movement Disorders</a>), <i>FOXG1-</i>related syndrome (OMIM <a href="https://omim.org/entry/613454" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613454</a>), <i>SYT1-</i>related disorder (OMIM <a href="https://omim.org/entry/185605" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">185605</a>), <a href="/books/n/gene/rapid-odp/"><i>ATP1A3</i>-related neurologic disorders</a>, and <i>GNAO1</i>-related diseases (OMIM <a href="https://omim.org/entry/615473" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615473</a>).</p><p><b>Monogenic juvenile parkinsonism syndromes</b> due to mutation of the following genes [<a class="bk_pop" href="#slc6a3-dtds.REF.garciacazorla.2014.627">Garcia-Cazorla &#x00026; Duarte 2014</a>] may mimic classic early-onset and atypical later-onset DTDS:</p><ul><li class="half_rhythm"><div><i>PARK2</i> (see <a href="/books/n/gene/jpd/">Parkin Type of Early-Onset Parkinson Disease</a>)</div></li><li class="half_rhythm"><div><i>PINK1</i> (see <a href="/books/n/gene/pink1-pd/"><i>PINK1</i> Type of Young-Onset Parkinson Disease</a>)</div></li><li class="half_rhythm"><div><i>DJ1</i> (see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>)</div></li><li class="half_rhythm"><div><i>ATXN2</i> (SCA2) (see <a href="/books/n/gene/sca2/">SCA2</a>)</div></li><li class="half_rhythm"><div><i>ATXN3</i> (SCA3) (see <a href="/books/n/gene/sca3/">SCA3</a>)</div></li><li class="half_rhythm"><div><i>ATP1A3</i> (see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>)</div></li><li class="half_rhythm"><div><i>PRKRA</i> (see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>)</div></li><li class="half_rhythm"><div><i>FBXO7</i> (OMIM <a href="https://omim.org/entry/260300" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">260300</a>)</div></li><li class="half_rhythm"><div><i>SPG11</i> (see <a href="/books/n/gene/spg11/">Spastic Paraplegia 11</a>)</div></li><li class="half_rhythm"><div><i>DNAJC6</i> (OMIM <a href="https://omim.org/entry/608375" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608375</a>)</div></li></ul><p><b>Disorders of brain metal accumulation.</b>
<a href="/books/n/gene/wilson/">Wilson disease</a>, <a href="/books/n/gene/nbia-ov/">neurodegeneration with brain iron accumulation</a> (NBIA), and <a href="/books/n/gene/hmdpc/">dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease</a> may mimic <i>SLC6A3-</i>related DTDS. Brain MRI can assist in the diagnosis of these disorders [<a class="bk_pop" href="#slc6a3-dtds.REF.tuschl.2012.457">Tuschl et al 2012</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.bandmann.2015.103">Bandmann et al 2015</a>]; see also <a href="/books/n/gene/nbia-ov/">Neurodegeneration with Brain Iron Accumulation</a>.</p><p><b>Other.</b> Meningoencephalitis; autoimmune, hypoxia, drug-induced, post-infectious, and monogenic causes of striatal necrosis; tumors; and <a href="/books/n/gene/rett/">Rett syndrome</a> should be considered as well [<a class="bk_pop" href="#slc6a3-dtds.REF.garciacazorla.2014.627">Garcia-Cazorla &#x00026; Duarte 2014</a>].</p></div><div id="slc6a3-dtds.Management"><h2 id="_slc6a3-dtds_Management_">Management</h2><div id="slc6a3-dtds.Evaluations_Following_Initia"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with a <i>SLC6A3-</i>related dopamine transporter deficiency syndrome (DTDS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Neurologic assessment of the movement disorder</div></li><li class="half_rhythm"><div>Ophthalmology assessment of vision and eye movements</div></li><li class="half_rhythm"><div>Evaluation of caloric intake and feeding by a nutritionist</div></li><li class="half_rhythm"><div>Speech and language therapy assessment of communication and swallowing</div></li><li class="half_rhythm"><div>Physiotherapy evaluation of postural issues and tone</div></li><li class="half_rhythm"><div>Occupational therapy to provide suitable aids for communication, mobility, and home adaptations</div></li><li class="half_rhythm"><div>Hip and spine x-rays to evaluate for hip dislocation and spinal deformity</div></li><li class="half_rhythm"><div>Orthopedic review of any fixed contractures / joint dislocations</div></li><li class="half_rhythm"><div>Pediatric physician-led care for evaluation of general issues such as drooling, gastroesophageal reflux disease, constipation, disturbed sleeping, and pressure sores</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="slc6a3-dtds.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>A multidisciplinary approach to the long-term management of this progressive disorder is optimal [<a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014b.275">Ng et al 2014b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2015">Kurian &#x00026; Assmann 2015</a>].</p><p>As first principle, risk factors that exacerbate the movement disorder should be avoided, including patient discomfort, poor body positioning, and pain (e.g., from constipation, urinary retention, pressure sores, undetected fractures). Early referral for nasogastric feeding or percutaneous gastrostomy is appropriate if oral feeding becomes problematic.</p><p><b>Treatment for the palliative control of symptoms</b> includes the following [<a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014b.275">Ng et al 2014b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2015">Kurian &#x00026; Assmann 2015</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">Tetrabenazine and benzodiazepines may be useful in controlling chorea and dyskinesia in early stages of the disease. Chloral hydrate may also help during exacerbations or to aid sleep.</div></li><li class="half_rhythm"><div class="half_rhythm">Dystonia is more difficult to control and treatment often includes pramipexole and ropinirole as first-line agents (as few patients respond to levodopa/carbidopa and any response is usually modest and not sustained).</div><div class="half_rhythm">Adjuncts, such as the anticholinergic trihexyphenidyl, are often needed. Baclofen, gabapentin, and clonidine may also be tried for severe dystonia.</div><div class="half_rhythm">Benzodiazepines and chloral hydrate can be useful for exacerbations of dystonia or status dystonicus. Although the role of atypical tranquilizers (e.g., zopiclone) is not yet established, they have been used successfully in individual cases.</div></li><li class="half_rhythm"><div class="half_rhythm">Surgical interventions such as intrathecal baclofen and deep brain stimulation have been used on rare occasions late in the disease course when dystonia is severe; therapeutic benefit is limited [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Optimum management of tone with medical therapies and regular physiotherapy evaluation reduce risk of contracture development. Focal botulinum toxin may be considered for emerging limb contractures and to prevent hip dislocation.</div></li><li class="half_rhythm"><div class="half_rhythm">For the treatment of vomiting, anti-emetics such as the anti-serotoninergic agents (e.g., ondansetron) potentially have fewer side effects than other agents.</div></li></ul><p><b>Treatment of status dystonicus.</b> Standard protocols are used in an intensive care setting. Anesthetic agents, GABA-ergic medication (including GABA-A receptor agonists such as benzodiazepines, GABA-enhancing medications such as gabapentin or phenobarbitone, and GABA-B receptor agonists like baclofen), further anticholinergics, and alpha adrenergic agents such as clonidine may be used. For severe life-threatening or medically intractable status dystonicus, intrathecal baclofen and pallidal deep brain stimulation may be considered.</p></div><div id="slc6a3-dtds.Prevention_of_Secondary_Comp"><h3>Prevention of Secondary Complications</h3><p>Consider influenza vaccine, prophylactic antibiotics, and chest physiotherapy for patients prone to chest infections especially during winter months.</p></div><div id="slc6a3-dtds.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Evaluation every six to 12 months for early evidence of hip dislocation and/or spinal deformity</div></li><li class="half_rhythm"><div>Regular swallowing assessment to evaluate risk for aspiration</div></li><li class="half_rhythm"><div>Regular assessment by a dietitian/nutritionist to ensure adequate caloric intake</div></li></ul></div><div id="slc6a3-dtds.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Although dopamine agonists are used as first-line treatment of dystonia in <i>SLC6A3-</i>related DTDS, bromocriptine and pergolide are generally avoided due to increased risk of pulmonary, retroperitoneal, and pericardial fibrosis.</p><p>Drugs with anti-dopaminergic side effects (e.g., some antihistamines, sedatives, and dimenhydrinate) may exacerbate the movement disorder.</p></div><div id="slc6a3-dtds.Evaluation_of_Relatives_at_R"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#slc6a3-dtds.Related_Genetic_Counseling_I">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="slc6a3-dtds.Therapies_Under_Investigatio"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="slc6a3-dtds.Genetic_Counseling"><h2 id="_slc6a3-dtds_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="slc6a3-dtds.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>SLC6A3-</i>related dopamine transporter deficiency syndrome (DTDS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="slc6a3-dtds.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are usually obligate heterozygotes (i.e., carriers of one <i>SLC6A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>To date, there are no reports of individuals with <i>SLC6A3</i>-related DTDS having children, but this may be a theoretic possibility for those with the atypical form of disease.</div></li><li class="half_rhythm"><div>The offspring of an individual with <i>SLC6A3</i>-related DTDS would be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (based on the assumption that the offspring's partner is not a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>).</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>SLC6A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="slc6a3-dtds.Carrier_Heterozygote_Detecti"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SLC6A3</i> pathogenic variants in the family.</p></div><div id="slc6a3-dtds.Related_Genetic_Counseling_I"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="slc6a3-dtds.Prenatal_Testing_and_Preimpl"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SLC6A3</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for <i>SLC6A3-</i>related DTDS are possible.</p></div></div><div id="slc6a3-dtds.Resources"><h2 id="_slc6a3-dtds_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><p>No specific resources for <i>SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome have been identified by <i>GeneReviews</i> staff.</p></div><div id="slc6a3-dtds.Molecular_Genetics"><h2 id="_slc6a3-dtds_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="slc6a3-dtds.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>SLC6A3-Related Dopamine Transported Deficiency Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK442323/table/slc6a3-dtds.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__slc6a3-dtds.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_slc6a3-dtds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6531" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SLC6A3</i></a></td><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6531" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">5p15<wbr style="display:inline-block"></wbr>​.33</a></td><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q01959" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sodium-dependent dopamine transporter</a></td><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/SLC6A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A3 @ LOVD</a></td><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SLC6A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A3</a></td><td headers="hd_b_slc6a3-dtds.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SLC6A3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SLC6A3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="slc6a3-dtds.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="slc6a3-dtds.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for SLC6A3-Related Dopamine Transported Deficiency Syndrome (<a href="/omim/126455,613135" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK442323/table/slc6a3-dtds.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__slc6a3-dtds.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/126455" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">126455</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, DOPAMINE), MEMBER 3; SLC6A3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613135" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613135</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PARKINSONISM-DYSTONIA, INFANTILE, 1; PKDYS1</td></tr></tbody></table></div></div><div id="slc6a3-dtds.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>To date, functional investigations indicate that <i>SLC6A3-</i>related DTDS results from loss of transporter function [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>]. <i>SLC6A3</i> encodes the dopamine transporter (DAT) that is expressed predominantly within the substantia nigra (projecting to the striatum) and in the midbrain ventral tegmental area (projecting to the hippocampus, nucleus accumbens, and corticolimbic areas). The transporter has a crucial role in mediating reuptake of dopamine from the synaptic cleft, thereby controlling dopamine homeostasis by regulating the duration and amplitude of synaptic dopaminergic transmission.</p><p>A number of <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> changes, and deletions have been reported in <i>SLC6A3-</i>related DTDS, and it is likely that for these pathogenic variants nonsense-mediated decay or absent/truncated protein are mechanistic factors in disease. Reported <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> substitutions result in mutated proteins that impair transporter function through a number of mechanisms including (i) reduced transporter activity, (ii) impaired dopamine recognition and/or binding affinity, (iii) decreased cell surface expression of the transporter, and (iv) abnormal posttranslational protein modification with impaired glycosylation [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>]. Abnormal DAT protein folding and transporter oligomerization are also postulated to play a role.</p><p><i>SLC6A3</i> pathogenic variants therefore impair the normal physiologic recycling of dopamine leading to presynaptic dopamine depletion. Excess dopamine in the synaptic cleft is metabolized to HVA, which can be detected on CSF analysis. High levels of synaptic dopamine may have downstream signaling effects on postsynaptic dopamine receptors, and are also likely to suppress tyrosine hydroxylase activity through action on D2 autoreceptors, thereby inhibiting presynaptic dopamine synthesis [<a class="bk_pop" href="#slc6a3-dtds.REF.blackstone.2009.1455">Blackstone 2009</a>].</p><p>A DAT knockout mouse model shows a number of features described in humans, including reduced growth, early hyperkinesia, and difficulties with feeding. Over time they develop abnormal clasping and kyphosis with progressive bradykinesia, reminiscent of the parkinsonism-dystonia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in humans [<a class="bk_pop" href="#slc6a3-dtds.REF.giros.1996.606">Giros et al 1996</a>].</p><p><b>Gene structure.</b> The protein-coding transcript <a href="/nuccore/NM_001044.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001044.4</a> (<a href="http://www.ensembl.org/Homo_sapiens/Transcript/Summary?g=ENSG00000142319;r=5:1392790-1445430;t=ENST00000270349" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ENST00000270349</a>) comprises 15 exons in total, 14 of which are coding.</p><p><b>Pathogenic variants.</b> To date, 20 individuals have been identified with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (i.e., <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>) pathogenic variants in <i>SLC6A3.</i></p><p>Pathogenic variants have been identified throughout the entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a> and flanking splice sites. No mutation hot spots or recurrent/common pathogenic variants have been identified. In these 20 individuals, 41 pathogenic variants including 27 <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> changes, one pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant, seven <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, and four intra-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> small deletions have been described. Large deletions have been described: a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> multiexon <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>] and a microdeletion/<a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> encompassing <i>SLC6A3</i> [Kurian, personal communication 2016].</p><p>Note that rare <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants in <i>SLC6A3</i> have been reported in individuals with bipolar disorder, attention-deficit/hyperactivity disorder, and autism spectrum disorder [<a class="bk_pop" href="#slc6a3-dtds.REF.hayden.2006.85">Hayden &#x00026; Nurnberger 2006</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hamilton.2013.1315">Hamilton et al 2013</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.bowton.2014.e464">Bowton et al 2014</a>] leading to the proposal that &#x02013; through currently unknown mechanisms &#x02013; this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> may confer risk for multiple complex psychiatric disorders [<a class="bk_pop" href="#slc6a3-dtds.REF.bowton.2014.e464">Bowton et al 2014</a>]. However, parents of individuals with DTDS have not manifested attention-deficit disorder or psychiatric diseases.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The gene transcript encodes a protein of 620 amino acids (<a href="/protein/NP_001035.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001035.1</a>). The dopamine transporter (DAT) is one of the solute carrier 6 (SLC6) transporters [<a class="bk_pop" href="#slc6a3-dtds.REF.br_er.2012.256">Br&#x000f6;er &#x00026; Gether 2012</a>]. Based on the crystal structure of a prokaryotic homolog [<a class="bk_pop" href="#slc6a3-dtds.REF.singh.2007.952">Singh et al 2007</a>], DAT comprises 12 transmembrane helices connected by a series of interconnecting extracellular and intracellular loops from the N- to C-terminus. The protein undergoes posttranslational modification prior to being expressed at the cell surface of the presynaptic membrane. Its role in the <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> of dopamine requires tandem transport of sodium and chloride ions across the cell membrane.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in the gene are postulated to lead to loss of transporter function and a number of pathogenic variants reported in the literature are pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, or deletions.</p><p>Functional studies indicate that for pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, mutated DAT displays impaired transporter function through a number of mechanisms including (i) reduced transporter activity, (ii) impaired dopamine recognition and binding affinity, (iii) decreased cell surface expression of the transporter, and (iv) abnormal posttranslational protein modification with impaired glycosylation [<a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2009.1595">Kurian et al 2009</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.kurian.2011b.54">Kurian et al 2011b</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.hansen.2014.3107">Hansen et al 2014</a>, <a class="bk_pop" href="#slc6a3-dtds.REF.ng.2014a.1107">Ng et al 2014a</a>].</p></div></div><div id="slc6a3-dtds.References"><h2 id="_slc6a3-dtds_References_">References</h2><div id="slc6a3-dtds.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.bandmann.2015.103">Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. <span><span class="ref-journal">Lancet Neurol. </span>2015;<span class="ref-vol">14</span>:103–13.</span> [<a href="/pmc/articles/PMC4336199/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4336199</span></a>] [<a href="/pubmed/25496901" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25496901</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.blackstone.2009.1455">Blackstone C. Infantile parkinsonism-dystonia: a dopamine "transportopathy". <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:1455–8.</span> [<a href="/pmc/articles/PMC2689103/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2689103</span></a>] [<a href="/pubmed/19504720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19504720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.bowton.2014.e464">Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, Matthies HJ, Erreger K, Galli A. SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. <span><span class="ref-journal">Transl Psychiatry. </span>2014;<span class="ref-vol">4</span>:e464.</span> [<a href="/pmc/articles/PMC4350523/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4350523</span></a>] [<a href="/pubmed/25313507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25313507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.br_er.2012.256">Br&#x000f6;er S, Gether U. The solute carrier 6 family of transporters. <span><span class="ref-journal">Br J Pharmacol. </span>2012;<span class="ref-vol">167</span>:256–78.</span> [<a href="/pmc/articles/PMC3481037/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3481037</span></a>] [<a href="/pubmed/22519513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22519513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.garciacazorla.2008.273">Garcia-Cazorla A, Duarte S, Serrano M, Nascimento A, Ormazabal A, Carrilho I, Briones P, Montoya J, Garesse R, Sala-Castellvi P, Pineda M, Artuch R. Mitochondrial diseases mimicking neurotransmitter defects. <span><span class="ref-journal">Mitochondrion. </span>2008;<span class="ref-vol">8</span>:273–8.</span> [<a href="/pubmed/18558519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18558519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.garciacazorla.2014.627">Garcia-Cazorla A, Duarte ST. Parkinsonism and inborn errors of metabolism. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:627–42.</span> [<a href="/pubmed/24906253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24906253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.giros.1996.606">Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. <span><span class="ref-journal">Nature. </span>1996;<span class="ref-vol">379</span>:606–12.</span> [<a href="/pubmed/8628395" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8628395</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.hamilton.2013.1315">Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Sahai MA, Cook EH, Gether U, McHaourab HS, Matthies HJ, Sutcliffe JS, Galli A, et al.  De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. <span><span class="ref-journal">Mol Psychiatry. </span>2013;<span class="ref-vol">18</span>:1315–23.</span> [<a href="/pmc/articles/PMC4046646/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4046646</span></a>] [<a href="/pubmed/23979605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23979605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.hansen.2014.3107">Hansen FH, Skj&#x000f8;rringe T, Yasmeen S, Arends NV, Sahai MA, Erreger K, Andreassen TF, Holy M, Hamilton PJ, Neergheen V, Karlsborg M, Newman AH, Pope S, Heales SJ, Friberg L, Law I, Pinborg LH, Sitte HH, Loland C, Shi L, Weinstein H, Galli A, Hjermind LE, M&#x000f8;ller LB, Gether U. Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. <span><span class="ref-journal">J Clin Invest. </span>2014;<span class="ref-vol">124</span>:3107–20.</span> [<a href="/pmc/articles/PMC4071392/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4071392</span></a>] [<a href="/pubmed/24911152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24911152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.hasselmann.2010.58">Hasselmann O, Blau N, Ramaekers VT, Quadros EV, Sequeira JM, Weissert M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. <span><span class="ref-journal">Mol Genet Metab. </span>2010;<span class="ref-vol">99</span>:58–61.</span> [<a href="/pubmed/19766516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19766516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.hayden.2006.85">Hayden EP, Nurnberger JI Jr. Molecular genetics of bipolar disorder. <span><span class="ref-journal">Genes Brain Behav. </span>2006;<span class="ref-vol">5</span>:85–95.</span> [<a href="/pubmed/16436192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16436192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.kurian.2015">Kurian MA, Assmann BE. The monoamine "transportopathies": Dopamine transporter deficiency syndrome and vesicular monoamine transporter deficiency. In: Hoffmann G, Blau N, eds. <em>Congenital Neurotransmitter Disorders: A Clinical Approach</em>. New York: Nova Science Publishers Inc; 2015:81-91.</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.kurian.2011a.721">Kurian MA, Gissen P, Smith M, Heales S Jr, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. <span><span class="ref-journal">Lancet Neurol. </span>2011a;<span class="ref-vol">10</span>:721–33.</span> [<a href="/pubmed/21777827" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21777827</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.kurian.2011b.54">Kurian MA, Li Y, Zhen J, Meyer E, Hai N, Christen HJ, Hoffmann GF, Jardine P, von Moers A, Mordekar SR, O'Callaghan F, Wassmer E, Wraige E, Dietrich C, Lewis T, Hyland K, Heales S Jr, Sanger T, Gissen P, Assmann BE, Reith ME, Maher ER. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. <span><span class="ref-journal">Lancet Neurol. </span>2011b;<span class="ref-vol">10</span>:54–62.</span> [<a href="/pmc/articles/PMC3002401/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3002401</span></a>] [<a href="/pubmed/21112253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21112253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.kurian.2009.1595">Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P, Morgan NV, Meyer E, Tee L, Pasha S, Wassmer E, Heales SJ, Gissen P, Reith ME, Maher ER. Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. <span><span class="ref-journal">J Clin Invest. </span>2009;<span class="ref-vol">119</span>:1595–603.</span> [<a href="/pmc/articles/PMC2689114/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2689114</span></a>] [<a href="/pubmed/19478460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19478460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.ng.2015.567">Ng J, Papandreou A, Heales SJ, Kurian MA. Monoamine neurotransmitter disorders-clinical advances and future perspectives. <span><span class="ref-journal">Nat Rev Neurol. </span>2015;<span class="ref-vol">11</span>:567–84.</span> [<a href="/pubmed/26392380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26392380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.ng.2014a.1107">Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, Rider NL, Morton DH, Strauss KA, Puffenberger EG, D'Agnano D, Anikster Y, Carducci C, Hyland K, Rotstein M, Leuzzi V, Borck G, Reith ME, Kurian MA. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. <span><span class="ref-journal">Brain. </span>2014a;<span class="ref-vol">137</span>:1107–19.</span> [<a href="/pmc/articles/PMC3959557/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3959557</span></a>] [<a href="/pubmed/24613933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24613933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.ng.2014b.275">Ng J, Heales SJ, Kurian MA. Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders. <span><span class="ref-journal">Paediatr Drugs. </span>2014b;<span class="ref-vol">16</span>:275–91.</span> [<a href="/pmc/articles/PMC4102824/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4102824</span></a>] [<a href="/pubmed/25011953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25011953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.pineda.2006.394">Pineda M, Ormazabal A, L&#x000f3;pez-Gallardo E, Nascimento A, Solano A, Herrero MD, Vilaseca MA, Briones P, Ib&#x000e1;&#x000f1;ez L, Montoya J, Artuch R. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:394–8.</span> [<a href="/pubmed/16365882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16365882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.tuschl.2012.457">Tuschl K, Clayton PT, Gospe SM Jr, Gulab S, Ibrahim S, Singhi P, Aulakh R, Ribeiro RT, Barsottini OG, Zaki MS, Del Rosario ML, Dyack S, Price V, Rideout A, Gordon K, Wevers RA, Chong WK, Mills PB. Syndrome of hepatic cirrhosis, dystonia, polycythemia, and hypermanganesemia caused by mutations in SLC30A10, a manganese transporter in man. <span><span class="ref-journal">Am J Hum Genet. </span>2012;<span class="ref-vol">90</span>:457–66.</span> [<a href="/pmc/articles/PMC3309187/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3309187</span></a>] [<a href="/pubmed/22341972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22341972</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.singh.2007.952">Singh SK, Yamashita A, Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">448</span>:952–6.</span> [<a href="/pubmed/17687333" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17687333</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="slc6a3-dtds.REF.yildiz.2017.49">Yildiz Y, Pektas E, Tokatli A, Haliloglu G. Hereditary dopamine transporter deficiency syndrome: challenges in diagnosis and treatment. <span><span class="ref-journal">Neuropediatrics. </span>2017;<span class="ref-vol">48</span>:49–52.</span> [<a href="/pubmed/27690368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27690368</span></a>]</div></li></ul></div></div><div id="slc6a3-dtds.Chapter_Notes"><h2 id="_slc6a3-dtds_Chapter_Notes_">Chapter Notes</h2><div id="slc6a3-dtds.Author_Notes"><h3>Author Notes</h3><p>Dr Manju Kurian<br />Developmental Neurosciences, UCL Institute of Child Health, London<br />Web: <a href="https://iris.ucl.ac.uk/iris/browse/profile?upi=MKURI59" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">iris.ucl.ac.uk/iris/browse/profile?upi=MKURI59</a></p></div><div id="slc6a3-dtds.Acknowledgments"><h3>Acknowledgments</h3><p>The author would like to thank and acknowledge the families and patients with DTDS. MAK is funded by a Wellcome Trust Intermediate Clinical Fellowship and receives funding from Rosetrees Trust.</p></div><div id="slc6a3-dtds.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>27 July 2017 (bp) Review posted live</div></li><li class="half_rhythm"><div>30 June 2015 (mak) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK442323</span><span class="label">PMID: <a href="/pubmed/28749637" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">28749637</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/slc39a14-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/sost/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK442323&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK442323/?report=reader">PubReader</a></li><li><a href="/books/NBK442323/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK442323" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK442323" style="display:none" title="Cite this Page"><div class="bk_tt">Kurian MA. SLC6A3-Related Dopamine Transporter Deficiency Syndrome. 2017 Jul 27. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK442323/pdf/Bookshelf_NBK442323.pdf">PDF version of this page</a> (438K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#slc6a3-dtds.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#slc6a3-dtds.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#slc6a3-dtds.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#slc6a3-dtds.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#slc6a3-dtds.Genetically_Related_Allelic" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#slc6a3-dtds.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#slc6a3-dtds.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#slc6a3-dtds.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#slc6a3-dtds.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#slc6a3-dtds.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#slc6a3-dtds.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#slc6a3-dtds.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6531[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SLC6A3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4428952" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4428952" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4428952" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4428952" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301718" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PLA2G6</i>-Associated Neurodegeneration<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gregory A, Kurian MA, Maher ER, Hogarth P, Hayflick SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301610" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y, Kish S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28541650" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tuschl K, Gregory A, Meyer E, Clayton PT, Hayflick SJ, Mills PB, Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=28749637" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=28749637" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04146939a66ee2badc05b2">SLC6A3-Related Dopamine Transporter Deficiency Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">SLC6A3-Related Dopamine Transporter Deficiency Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:01:13-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal106&amp;ncbi_phid=CE8DA0C1E0405F010000000006070241&amp;ncbi_session=CE8DA0C1E0414681_1543SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK442323%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK442323&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK442323/&amp;ncbi_pagename=SLC6A3-Related Dopamine Transporter Deficiency Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DA0C1E0414681_1543SID /projects/books/PBooks@5.22 portal106 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>